Effects of Fasting and Administration of Octreotide Acetate and Ulinastatin on Clinical Outcomes of Pancreatic Fistula After Pancreatoduodenectomy

Abstract

Objective Postoperative pancreatic fistula (POPF) following pancreaticoduodenectomy is the most serious complication of these surgical procedures; therefore, we examined the effectiveness of fasting, and administration of octreotide acetate and ulinastatin as a method of prevention. Summary of Background Data Although various drug therapies and surgical techniques have been used for the treatment of POPF, no decisive treatment for POPF exists. Methods The clinical course of 30 patients who developed POPF was retrospectively evaluated and compared among no dietary intake (n = 18), octreotide acetate (n = 8), and ulinastatin (n = 8) using an overlapping design. Patients were allocated to either the dietary intake or fasting (no dietary intake) group, and those in the no dietary intake group were further divided into the octreotide acetate or ulinastatin group. Results Length of hospitalization was longer for the no dietary intake group than for the dietary intake group (P = 0.002). When considering only grade B or C POPF cases, the no dietary intake group had a longer length of hospitalization and a higher white blood cell count on day 7 after the diagnosis of POPF than the dietary intake group (P < 0.05). The white blood cell count was also higher in the octreotide acetate group than in the ulinastatin group (P = 0.021). The length of hospitalization was shorter in the ulinastatin group than in the octreotide acetate group (P = 0.025). Conclusions The use of no dietary intake, octreotide acetate, and ulinastatin does not seem to contribute to the clinical course of patients with POPF after pancreatoduodenectomy.